These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 22742765)
1. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients. Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study. Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial]. Wang Z; Shan T; Liu Y; Ding S; Li C; Zhai Q; Chen X; Du B; Li Y; Zhang J; Wang H; Wu D Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Sep; 26(9):644-9. PubMed ID: 25230866 [TBL] [Abstract][Full Text] [Related]
5. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853 [TBL] [Abstract][Full Text] [Related]
7. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514 [TBL] [Abstract][Full Text] [Related]
8. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA; J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783 [TBL] [Abstract][Full Text] [Related]
9. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546 [TBL] [Abstract][Full Text] [Related]
10. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Shabaan AE; Nour I; Elsayed Eldegla H; Nasef N; Shouman B; Abdel-Hady H Pediatr Infect Dis J; 2017 Apr; 36(4):358-363. PubMed ID: 27918382 [TBL] [Abstract][Full Text] [Related]
11. Continuous infusion versus intermittent administration of meropenem in critically ill patients. Thalhammer F; Traunmüller F; El Menyawi I; Frass M; Hollenstein UM; Locker GJ; Stoiser B; Staudinger T; Thalhammer-Scherrer R; Burgmann H J Antimicrob Chemother; 1999 Apr; 43(4):523-7. PubMed ID: 10350382 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics. Chen M; Buurma V; Shah M; Fahim G Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562 [TBL] [Abstract][Full Text] [Related]
14. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160 [TBL] [Abstract][Full Text] [Related]
15. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. Dulhunty JM; Brett SJ; De Waele JJ; Rajbhandari D; Billot L; Cotta MO; Davis JS; Finfer S; Hammond NE; Knowles S; Liu X; McGuinness S; Mysore J; Paterson DL; Peake S; Rhodes A; Roberts JA; Roger C; Shirwadkar C; Starr T; Taylor C; Myburgh JA; Lipman J; JAMA; 2024 Aug; 332(8):629-637. PubMed ID: 38864155 [TBL] [Abstract][Full Text] [Related]
16. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Pea F; Viale P; Cojutti P; Furlanut M Antimicrob Agents Chemother; 2012 Dec; 56(12):6343-8. PubMed ID: 23045356 [TBL] [Abstract][Full Text] [Related]
17. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Langgartner J; Vasold A; Glück T; Reng M; Kees F Intensive Care Med; 2008 Jun; 34(6):1091-6. PubMed ID: 18297267 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Cies JJ; Moore WS; Dickerman MJ; Small C; Carella D; Chopra A; Parker J Pharmacotherapy; 2014 Oct; 34(10):e175-9. PubMed ID: 25146254 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial. Lertwattanachai T; Montakantikul P; Tangsujaritvijit V; Sanguanwit P; Sueajai J; Auparakkitanon S; Dilokpattanamongkol P J Intensive Care; 2020; 8():26. PubMed ID: 32318268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]